A detailed history of Ken Fisher (Fisher Asset Management, LLC) transactions in United Therapeutics Corp stock. As of the latest transaction made, Fisher Asset Management, LLC holds 5,155 shares of UTHR stock, worth $1.94 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,155
Previous 4,821 6.93%
Holding current value
$1.94 Million
Previous $1.11 Million 48.33%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$228.26 - $319.04 $76,238 - $106,559
334 Added 6.93%
5,155 $1.64 Million
Q1 2024

May 09, 2024

BUY
$210.76 - $249.51 $209,284 - $247,763
993 Added 25.94%
4,821 $1.11 Million
Q4 2023

Mar 05, 2024

BUY
$214.88 - $256.94 $20,843 - $24,923
97 Added 2.6%
3,828 $841,000
Q4 2023

Feb 06, 2024

BUY
$214.88 - $256.94 $24,066 - $28,777
112 Added 3.09%
3,731 $820,000
Q3 2023

Nov 13, 2023

SELL
$211.82 - $248.24 $154,628 - $181,215
-730 Reduced 16.79%
3,619 $817,000
Q2 2023

Dec 12, 2023

BUY
$205.19 - $232.99 $149,788 - $170,082
730 Added 20.17%
4,349 $960,000
Q2 2023

Aug 08, 2023

SELL
$205.19 - $232.99 $16,825 - $19,105
-82 Reduced 1.85%
4,349 $960,000
Q1 2023

Dec 12, 2023

BUY
$212.99 - $276.17 $150,583 - $195,252
707 Added 19.54%
4,326 $968,000
Q1 2023

May 01, 2023

BUY
$212.99 - $276.17 $2,555 - $3,314
12 Added 0.27%
4,431 $993,000
Q4 2022

Feb 03, 2023

BUY
$205.95 - $280.43 $910,093 - $1.24 Million
4,419 New
4,419 $1.23 Million
Q1 2018

Apr 19, 2018

BUY
$107.21 - $151.94 $48,351 - $68,524
451 Added 17.03%
3,100 $348,000
Q3 2017

Oct 17, 2017

BUY
$114.6 - $136.81 $303,575 - $362,409
2,649
2,649 $310,000

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $17.2B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track Ken Fisher's Portfolio

Track Ken Fisher Portfolio

Follow Ken Fisher (Fisher Asset Management, LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fisher Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fisher Asset Management, LLC and Ken Fisher with notifications on news.